Skip to main content
Clinical Trials/NCT05243394
NCT05243394
Recruiting
Not Applicable

Evaluating the Effects of a Treadmill Gait Training Protocol in a Gamified Virtual Reality Environment With tDCS in Parkinson's Disease: Randomized Controlled Trial

Universitat de Lleida1 site in 1 country66 target enrollmentJanuary 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson Disease
Sponsor
Universitat de Lleida
Enrollment
66
Locations
1
Primary Endpoint
Step cadence
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

The study aims to compare the effects of treadmill gait training in a gamified virtual reality environment with tDCS versus treadmill gait training in a gamified virtual reality environment versus treadmill training in people with Parkinson's Disease.

Detailed Description

Treadmill gait training has been stablished as a solid gait rehabilitation option for people with Parkinson's Disease. However, gait training by itself fails to address the cognitive aspect needed for safe walking, which could be affected by situations in which concurrent tasks must be managed simultaneously to gait. It also lacks motivational aspects key to keep people with Parkinson's Disease adhered to treatment. Virtual reality and gamification are posed as useful tools to address both these issues, turning training into a more engaging activity and allowing complicated gait situations to be trained in a safe environment. Transcranial direct current stimulation (tDCS) could be combined with these mentioned treatment options, which could reinforce the learning of motor and cognitive skills during training. The aim of this study is to evaluate the effects of the inclusion of a gamified virtual reality environment to a treadmill gait training program with tDCS in PD compared to the same training protocol with virtual reality and without it

Registry
clinicaltrials.gov
Start Date
January 2023
End Date
September 2024
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Universitat de Lleida
Responsible Party
Principal Investigator
Principal Investigator

Helena Fernández-Lago

Lecturer

Universitat de Lleida

Eligibility Criteria

Inclusion Criteria

  • Idiopathic Parkinson's Disease
  • Stage II - III in the Hoehn and Yahr Scale during ON state
  • Ability to walk for 10 minutes independently without stop

Exclusion Criteria

  • Significant cognitive decline based on mini mental status examination (MMSE \<23)
  • Severe auditory or visual deficits
  • Other neurological/psychiatric conditions
  • Any kind of cardiovascular complications that contraindicates physical activity
  • Clinical history of any brain surgery or deep brain stimulation device

Outcomes

Primary Outcomes

Step cadence

Time Frame: 14 weeks

Step cadence will be recorded while walking on a 10-meter aisle with an inertial sensor system while the patient is asked to walk at preferred, very slow, slow, medium, high and very high speed. Will be measured in Hertz (Hz).

Stride Length during Dual Task

Time Frame: 14 weeks

Stride length will be recorded while walking on a 10-meter aisle with an inertial sensor system while listening to an audio recording, in which patients will hear certain set words and will have to remember how many times they are mentioned (Phoneme Monitoring Paradigm Dual Task). Participants will be asked to walk at preferred speed. Will be measured in meters (m).

Step cadence during Dual Task

Time Frame: 14 weeks

Step cadence will be recorded while walking on a 10-meter aisle with an inertial sensor system while listening to an audio recording, in which patients will hear certain set words and will have to remember how many times they are mentioned (Phoneme Monitoring Paradigm Dual Task). Participants will be asked to walk at preferred speed. Will be measured in Hertz (Hz).

Stride Length Variation Coeficient

Time Frame: 14 weeks

Based on standard deviation and mean values of Stride Length data, a new variable will be calculated to assess the variability of stride length in participants' gait. Formula will be the following: (Standard deviation/mean Stride Length)100

Step Cadence Variation Coeficient during Dual Task

Time Frame: 14 weeks

Based on standard deviation and mean values of step cadence data during Dual Task, a new variable will be calculated to assess the variability of step cadence in participants' gait. Formula will be the following (data from Dual Task variable): (Standard deviation/mean Step Cadence)100

Speed

Time Frame: 14 weeks

Speed will be recorded while walking on a 10-meter aisle with an inertial sensor system while the patient is asked to walk at preferred, very slow, slow, medium, high and very high speed. Will be measured in meters per second (m/s).

Speed during Dual Task

Time Frame: 14 weeks

Speed will be recorded while walking on a 10-meter aisle with an inertial sensor system while listening to an audio recording, in which patients will hear certain set words and will have to remember how many times they are mentioned (Phoneme Monitoring Paradigm Dual Task). Participants will be asked to walk at preferred speed. Will be measured in meters per second (m/s).

Stride Length Variation Coeficient during Dual Task

Time Frame: 14 weeks

Based on standard deviation and mean values of Stride Length data, a new variable will be calculated to assess the variability of stride length in participants' gait. Formula will be the following (data from Dual Task variable): (Standard deviation/mean Stride Length)100

Step Cadence Variation Coeficient

Time Frame: 14 weeks

Based on standard deviation and mean values of step cadence data during Dual Task, a new variable will be calculated to assess the variability of step cadence in participants' gait. Formula will be the following: (Standard deviation/mean Step Cadence)100

Stride lenght

Time Frame: 14 weeks

Stride length will be recorded while walking on a 10-meter aisle with an inertial sensor system while the patient is asked to walk at preferred, very slow, slow, medium, high and very high speed. Will be measured in meters (m).

Secondary Outcomes

  • Montreal Cognitive Assessment(14 weeks)
  • MiniBest Test(14 weeks)
  • Unified Parkinson's Disease Rating Scale (UPDRS)(14 weeks)
  • Total Cognitive Performance(14 weeks)
  • Hoehn & Yahr(14 weeks)
  • Parkinson's Disease Questionnaire 39(14 weeks)

Study Sites (1)

Loading locations...

Similar Trials